← Back to Search

Muscle Relaxant

Cyclobenzaprine for Post-Traumatic Stress Disorder (OASIS Trial)

Worcester, MA
Phase 2
Waitlist Available
Led By Christopher Jones, MD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 18 years and ≤ 55 years of age
Pain severity in the ED ≥ 4 (0-10 numeric rating scale)
Must not have
Plans for hospital admission
Currently in the acute recovery phase of myocardial infarction
Timeline
Screening 3 weeks
Treatment Varies
Follow Up min 30, hour 1, 6, 12, day 1, 2, 3, week 1, 2, 3, 5, 6, 8, 11, 12 after mvc

Summary

This trial will test if a medication called TNX-102 SL can help reduce symptoms and behavioral changes in patients who go to the emergency department after a car accident. The study will involve 180 participants

See full description
Who is the study for?
This trial is for individuals who have recently been in a motor vehicle collision and are at high risk of developing acute stress reactions or disorders. Participants will receive treatment shortly after the event and must be willing to undergo assessments over several weeks.Check my eligibility
What is being tested?
The study tests if TNX-102 SL, taken sublingually, can reduce symptoms of acute stress reaction/disorder right after a traumatic event like a car crash. It's compared with a placebo in a double-blind setup where neither doctors nor patients know who gets the real medicine.See study design
What are the potential side effects?
Possible side effects aren't specified here but generally, Cyclobenzaprine may cause drowsiness, dry mouth, fatigue, headache and dizziness. Any adverse events during the trial will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 55 years old.
 show original
Select...
My pain level is 4 or higher on a scale of 0 to 10.
 show original
Select...
I was admitted to the emergency department within a day after a car accident.
 show original
Select...
I expect to go home after my emergency department visit.
 show original
Select...
I cannot have children due to surgery or being postmenopausal for over a year.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am scheduled to be admitted to the hospital.
 show original
Select...
I am currently recovering from a recent heart attack.
 show original
Select...
I am able to make my own medical decisions.
 show original
Select...
I have a serious injury, like a major bone break.
 show original
Select...
I have been taking more than 20 mg of morphine daily before my injury.
 show original
Select...
I do not have active psychosis or thoughts of harming myself or others.
 show original
Select...
I am allergic to cyclobenzaprine or ingredients in TNX-102 SL.
 show original
Select...
My liver or kidney function is not normal.
 show original
Select...
I have a history of urinary issues, glaucoma, eye pressure problems, or an overactive thyroid.
 show original
Select...
I have a history of heart rhythm problems or heart failure.
 show original
Select...
I am not taking any prohibited medications listed in the trial guidelines.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~min 30, hour 1, 6, 12, day 1, 2, 3, week 1, 2, 3, 5, 6, 8, 11, 12 after mvc
This trial's timeline: 3 weeks for screening, Varies for treatment, and min 30, hour 1, 6, 12, day 1, 2, 3, week 1, 2, 3, 5, 6, 8, 11, 12 after mvc for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in ASD Score
Secondary study objectives
Change in Depressive Symptoms Score
Change in PTSD Symptoms
Change in Pain Symptom Score
+5 more

Side effects data

From 2017 Phase 3 trial • 180 Patients • NCT02814565
20%
Somnolence
7%
Dry mouth
1%
Disruptive mood dysregulation disorder
1%
Sleep disorder
1%
Rhinitis
1%
Dysgeusia
1%
Poor quality sleep
1%
Anxiety
1%
Flatulence
1%
Toothache
1%
Influenza
1%
Dizziness
1%
Tachycardia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cyclobenzaprine HCl 15 mg
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cyclobenzaprine HClExperimental Treatment1 Intervention
Participants will be instructed to take a half dose (equivalent to 1 tablet, 2.8 mg) of placebo in the ED as part of enrollment procedures. If the time between the first half dose and the planned bedtime of the participant is less than 6 hours, participants will be instructed to take 1 tablet (half dose) the first night at bedtime. If the time between the first half dose and planned bedtime of the participant is greater than or equal to 6 hours, then participants will be instructed to take a full dose (equivalent to 2 tablets) the first night. Over the following 13 days, all participants will be instructed to take a full dose of the study drug at bedtime. Each participant will receive 29 tablets and take either 28 or 29 tablets total for the duration of study participation.
Group II: PlaceboPlacebo Group1 Intervention
Participants will be instructed to take a half dose (equivalent to 1 tablet, 2.8 mg) of placebo in the ED as part of enrollment procedures. The placebo is the same formulation as active except the Cyclobenzaprine HCl content is replaced by Mannitol to maintain the same tablet weight and dimensions. If the time between the first half dose and the planned bedtime of the participant is less than 6 hours, participants will be instructed to take 1 tablet (half dose) the first night at bedtime. If the time between the first half dose and planned bedtime of the participant is greater than or equal to 6 hours, then participants will be instructed to take a full dose (equivalent to 2 tablets) the first night. Over the following 13 days, all participants will be instructed to take a full dose of the study drug at bedtime. Each participant will receive 29 tablets and take either 28 or 29 tablets total for the duration of study participation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclobenzaprine HCl
2016
Completed Phase 3
~180

Find a Location

Closest Location:University of Kansas Medical Center· Kansas City, KS· 198 miles

Who is running the clinical trial?

Mclean HospitalOTHER
219 Previous Clinical Trials
22,211 Total Patients Enrolled
Cooper University Health CareOTHER
1 Previous Clinical Trials
1,771 Total Patients Enrolled
Tonix Pharmaceuticals, Inc.Industry Sponsor
30 Previous Clinical Trials
4,784 Total Patients Enrolled
University of North Carolina, Chapel HillLead Sponsor
1,580 Previous Clinical Trials
4,326,896 Total Patients Enrolled
United States Department of DefenseFED
931 Previous Clinical Trials
335,885 Total Patients Enrolled
Christopher Jones, MDPrincipal InvestigatorCooper University Health Care
2 Previous Clinical Trials
170 Total Patients Enrolled
Samuel McLean, MDPrincipal InvestigatorUniversity of North Carollina at Chapel Hill
~112 spots leftby Sep 2025